- Home
- LEU vs ANAB Comparison
LEU vs ANAB Comparison
Compare LEU & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- ANAB
- Stock Information
- Founded
- LEU 1998
- ANAB 2005
- Country
- LEU United States
- ANAB United States
- Employees
- LEU N/A
- ANAB N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- LEU Industrials
- ANAB Health Care
- Exchange
- LEU Nasdaq
- ANAB Nasdaq
- Market Cap
- LEU 599.9M
- ANAB 600.4M
- IPO Year
- LEU 1998
- ANAB 2017
- Fundamental
- Price
- LEU $70.31
- ANAB $19.22
- Analyst Decision
- LEU Buy
- ANAB Buy
- Analyst Count
- LEU 2
- ANAB 11
- Target Price
- LEU $92.00
- ANAB $54.64
- AVG Volume (30 Days)
- LEU 2.0M
- ANAB 622.4K
- Earning Date
- LEU 10-28-2024
- ANAB 11-05-2024
- Dividend Yield
- LEU N/A
- ANAB N/A
- EPS Growth
- LEU 50.42
- ANAB N/A
- EPS
- LEU 4.70
- ANAB N/A
- Revenue
- LEU $394,000,000.00
- ANAB $57,172,000.00
- Revenue This Year
- LEU $25.25
- ANAB $207.49
- Revenue Next Year
- LEU $2.84
- ANAB N/A
- P/E Ratio
- LEU $14.93
- ANAB N/A
- Revenue Growth
- LEU 14.94
- ANAB 282.17
- 52 Week Low
- LEU $33.51
- ANAB $13.36
- 52 Week High
- LEU $118.36
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- LEU 42.01
- ANAB 27.42
- Support Level
- LEU $72.71
- ANAB $20.81
- Resistance Level
- LEU $95.00
- ANAB $22.94
- Average True Range (ATR)
- LEU 10.97
- ANAB 1.58
- MACD
- LEU -3.54
- ANAB -0.18
- Stochastic Oscillator
- LEU 3.34
- ANAB 5.58
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).